Our top pick for
Royalty Pharma plc is a biotechnology business based in the US. Royalty Pharma shares (RPRX) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||USD$27.6887 - USD$55.8717|
|50-day moving average||USD$49.0342|
|200-day moving average||USD$43.9411|
|Wall St. target price||USD$52.14|
|Dividend yield||USD$0.68 (1.42%)|
|Earnings per share (TTM)||USD$-0.621|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Royalty Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Royalty Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Royalty Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Royalty Pharma shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Royalty Pharma's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Royalty Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.6 billion.
The EBITDA is a measure of a Royalty Pharma's overall financial performance and is widely used to measure a its profitability.
To put Royalty Pharma's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||USD$2.1 billion|
|Operating margin TTM||75.17%|
|Gross profit TTM||USD$1.9 billion|
|Return on assets TTM||0%|
|Return on equity TTM||21.36%|
|Market capitalisation||USD$29.3 billion|
TTM: trailing 12 months
There are currently 8.7 million Royalty Pharma shares held short by investors – that's known as Royalty Pharma's "short interest". This figure is 3.3% down from 9.0 million last month.
There are a few different ways that this level of interest in shorting Royalty Pharma shares can be evaluated.
Royalty Pharma's "short interest ratio" (SIR) is the quantity of Royalty Pharma shares currently shorted divided by the average quantity of Royalty Pharma shares traded daily (recently around 3.4 million). Royalty Pharma's SIR currently stands at 2.6. In other words for every 100,000 Royalty Pharma shares traded daily on the market, roughly 2600 shares are currently held short.
To gain some more context, you can compare Royalty Pharma's short interest ratio against those of similar companies.
However Royalty Pharma's short interest can also be evaluated against the total number of Royalty Pharma shares, or, against the total number of tradable Royalty Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Royalty Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Royalty Pharma shares in existence, roughly 10 shares are currently held short) or 0.0305% of the tradable shares (for every 100,000 tradable Royalty Pharma shares, roughly 31 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Royalty Pharma.
Find out more about how you can short Royalty Pharma stock.
Dividend payout ratio: 24.03% of net profits
Recently Royalty Pharma has paid out, on average, around 24.03% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.42% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Royalty Pharma shareholders could enjoy a 1.42% return on their shares, in the form of dividend payments. In Royalty Pharma's case, that would currently equate to about $0.68 per share.
While Royalty Pharma's payout ratio might seem low, this can signify that Royalty Pharma is investing more in its future growth.
Royalty Pharma's most recent dividend payout was on 15 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 18 February 2021 (the "ex-dividend date").
Royalty Pharma's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. The company has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.